Table 2.
Literature review (from the year 2005 to August 2020).
| Authors | Intervention (study design) | Results | Follow-up duration |
|---|---|---|---|
| Our study | IL bleomycin only (retrospective case series) | CC (89.47%), RR (15.78%) | 3 months |
| Barkat et al. [12] | IL bleomycin vs. placebo (RCT) | Bleomycin = dermoscopic clearance (69.3%); CC (88.5%), CC of placebo (0%) | 3 months |
| Pasquali et al. [13] | IL bleomycin + electropolation vs. IL bleomycin only (prospective case series) | CC of IL bleomycin + electroporation (78%), bleomycin only (16%) | 3 months |
| Dhar et al. [8] | IL bleomycin vs. cryotherapy (RCT) | CC of bleomycin (94.9%); cryotherapy (76.5%); RR (13%) | 8 weeks |
| Adalatkhah et al. [14] | IL bleomycin vs. cryotherapy (RCT) | CC of bleomycin (86%), cryotherapy (68%) | 6 weeks |
| Al-Naggar et al. [15] | IL bleomycin vs. microneedling assisted topical bleomycin spray (RCT) | CC of IL bleomycin (70%), CC of microneedling-assisted topical spray (83.3%) | 6 months |
| Soni et al. [9] | IL bleomycin vs. placebo (RCT) | CC of IL bleomycin (96.47%) vs. placebo (11.11%) | 12 months |
| Salk and Douglas [16] | IL bleomycin only (prospective study) | CC (87%), RR (19.35%) | 6 months |
| Alghamdi and Khurram [17] | Translesional multipuncture technique with 0.1 U/ml concentration for periungual warts (prospective study) | CC (86.6%), RR (13.33%) | 6 months |
| Alghamdi and Khurram [11] | Translesional multipuncture technique with 0.1 U/ml concentration for plantar warts (prospective study) | CC (74%), no response (13%), RR: 9.5% | 3 months |
| Aziz-Jalali et al. [5] | IL bleomycin (retrospective study) | CC (73%), RR (23%) | 6 months |
RCT: randomized controlled trial, CC: clinical clearance, RR: recurrence rate.